AstraZeneca buys Novo Holdings portfolio company Amolyt in potential $1bn+ deal Novo Holdings A/S and Sofinnova Partners, two leading life sciences investors, made headlines on Thursday when portfolio company Amolyt Pharma entered into a definitive agreement to be acquired by AstraZeneca at a purchase price of US$800 million upfront and a potential milestone payment of […]
Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]
Combination of real time scientific databases with proprietary data will enable venture capital firm to enhance deal origination and portfolio growth through data-driven insights and strengthened entrepreneurial partnerships PARIS, France – December 5, 2023 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the […]
Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions Paratek adds ‘final-mile’ capabilities to AMR efforts COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health […]
More than hangover-busting aspirin will be in order at the biopharma industry’s biggest week in London. The capital will host a gruelling conference double header, beginning with the LSX Inv€$tival Showcase on Monday 13th November, followed by the Jefferies London Healthcare Conference on Tuesday 14th November. With investors and biopharma business leaders descending on the […]
